Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics.

Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M, Gopalakrishnan V, Lacomis D, Cudkowicz M, Bowser R.

Muscle Nerve. 2010 Jul;42(1):104-11. doi: 10.1002/mus.21683.

2.

Biomarkers for amyotrophic lateral sclerosis.

Bowser R, Cudkowicz M, Kaddurah-Daouk R.

Expert Rev Mol Diagn. 2006 May;6(3):387-98. Review.

PMID:
16706741
3.

Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.

Ekegren T, Hanrieder J, Bergquist J.

J Mass Spectrom. 2008 May;43(5):559-71. doi: 10.1002/jms.1409. Review.

PMID:
18416436
4.

Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.

Xu Z, Henderson RD, David M, McCombe PA.

PLoS One. 2016 Oct 12;11(10):e0164625. doi: 10.1371/journal.pone.0164625. eCollection 2016. Review.

5.

Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Kolarcik C, Bowser R.

Mol Diagn Ther. 2006;10(5):281-92. Review.

PMID:
17022691
6.

Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery.

Krüger T, Lautenschläger J, Grosskreutz J, Rhode H.

Proteomics Clin Appl. 2013 Jan;7(1-2):123-35. doi: 10.1002/prca.201200067. Review.

PMID:
23129563
7.

Protein biomarkers for amyotrophic lateral sclerosis.

Ryberg H, Bowser R.

Expert Rev Proteomics. 2008 Apr;5(2):249-62. doi: 10.1586/14789450.5.2.249. Review.

PMID:
18466055
8.

Emerging molecular biomarker targets for amyotrophic lateral sclerosis.

Costa J, de Carvalho M.

Clin Chim Acta. 2016 Apr 1;455:7-14. doi: 10.1016/j.cca.2016.01.011. Epub 2016 Jan 14. Review.

PMID:
26774696
9.

[Biomarkers for amyotrophic lateral sclerosis].

Tokuda T.

Brain Nerve. 2012 May;64(5):515-23. Review. Japanese.

PMID:
22570065
10.

Applying proteomics to the diagnosis and treatment of ALS and related diseases.

Bowser R, Lacomis D.

Muscle Nerve. 2009 Nov;40(5):753-62. doi: 10.1002/mus.21488. Review.

11.

[What are the applications of biomarkers in ALS today?].

Blasco H, Corcia P, Pradat PF.

Presse Med. 2014 May;43(5):569-79. doi: 10.1016/j.lpm.2013.12.014. Epub 2014 Apr 29. Review. French.

PMID:
24785140
12.

Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis.

Turner MR, Benatar M.

Muscle Nerve. 2015 Jan;51(1):14-8. doi: 10.1002/mus.24470. Epub 2014 Nov 24. Review.

13.

Motor neuron disease in 2014. Biomarkers for ALS--in search of the Promised Land.

Chiò A, Traynor BJ.

Nat Rev Neurol. 2015 Feb;11(2):72-4. doi: 10.1038/nrneurol.2014.250. Epub 2014 Dec 23. Review.

14.

Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations.

Bowser R, Turner MR, Shefner J.

Nat Rev Neurol. 2011 Oct 11;7(11):631-8. doi: 10.1038/nrneurol.2011.151. Review.

PMID:
21989244
15.

ALS biomarkers for therapy development: State of the field and future directions.

Benatar M, Boylan K, Jeromin A, Rutkove SB, Berry J, Atassi N, Bruijn L.

Muscle Nerve. 2016 Feb;53(2):169-82. doi: 10.1002/mus.24979. Epub 2015 Dec 29. Review.

16.

Use of biomarkers in ALS drug development and clinical trials.

Bakkar N, Boehringer A, Bowser R.

Brain Res. 2015 May 14;1607:94-107. doi: 10.1016/j.brainres.2014.10.031. Epub 2014 Oct 24. Review.

17.

Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis.

Vu LT, Bowser R.

Neurotherapeutics. 2017 Jan;14(1):119-134. doi: 10.1007/s13311-016-0503-x. Review.

PMID:
27933485
18.

Neuroproteomic profiling of human body fluids.

Häggmark A, Schwenk JM, Nilsson P.

Proteomics Clin Appl. 2016 Apr;10(4):485-502. doi: 10.1002/prca.201500065. Epub 2015 Oct 12. Review.

PMID:
26286680
19.

New developments and future opportunities in biomarkers for amyotrophic lateral sclerosis.

Chen X, Shang HF.

Transl Neurodegener. 2015 Sep 30;4:17. doi: 10.1186/s40035-015-0040-2. eCollection 2015. Review.

Supplemental Content

Support Center